Targeted Neurodegeneration Clene Nanomedicine focuses on mitochondrial health and neuronal protection to treat neurodegenerative diseases, presenting a compelling opportunity to engage with researchers and care teams in ALS, Parkinson’s, and MS who are seeking disease-modifying approaches.

Clinical Stage Advantage As a late clinical-stage biopharma with CNM-Au8 in multiple trials, Clene offers potential partnership or co-development discussions for late-stage logistics, manufacturing scalability, and potential commercialization alignment once trials mature.

Mitochondrial & NAD Pathways CNM-Au8 targets mitochondrial function and the NAD pathway, addressing a shared interest area for contract manufacturers, diagnostic collaborators, and platform partners focusing on energy metabolism, oxidative stress reduction, and related biomarkers.

Outreach & Visibility Clene actively participates in investor conferences and maintains press coverage; this signals openness to third-party collaboration, licensing, or strategic partnerships and presents timely touchpoints for BD outreach and investor-aligned deals.

Operational Footprint With headquarters in Salt Lake City and R&D/manufacturing in Maryland, Clene offers geographic touchpoints for regional partnerships, contract manufacturing, and centralized quality/compliance discussions suitable for US-based collaborators.